Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Keogh

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Journal of the National Cancer Institute|November 6, 1996
Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy TrialG S Omenn, G E Goodman, M D Thornquist, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D Kim, Shannon McDonough, Anthony B El-Khoueiry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
Journal of Neuro-Oncology|November 4, 2017
Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling errorBrendan J McCullough, Valerie Ader, Brian Aguedan, et al.
Stroke|October 18, 2019
Contralateral Hemispheric Cerebral Blood Flow Measured With Arterial Spin Labeling Can Predict Outcome in Acute StrokeThoralf Thamm, Jia Guo, Jarrett Rosenberg, et al.
Clinical Breast Cancer|October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5John W Smith, Marc E Buyse, Priya Rastogi, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Journal of the National Cancer Institute|November 6, 1996
Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy TrialG S Omenn, G E Goodman, M D Thornquist, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D Kim, Shannon McDonough, Anthony B El-Khoueiry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
Journal of Neuro-Oncology|November 4, 2017
Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling errorBrendan J McCullough, Valerie Ader, Brian Aguedan, et al.
Stroke|October 18, 2019
Contralateral Hemispheric Cerebral Blood Flow Measured With Arterial Spin Labeling Can Predict Outcome in Acute StrokeThoralf Thamm, Jia Guo, Jarrett Rosenberg, et al.
Clinical Breast Cancer|October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5John W Smith, Marc E Buyse, Priya Rastogi, et al.
Pageof 14